Techno Horizon Co.,Ltd. (TYO:6629)
Japan · Delayed Price · Currency is JPY 396.00
+1.00 (0.25%)
Aug 12, 2025, 3:30 PM JST
G1 Therapeutics Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2021 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2021 |
| 49,909 | 50,624 | 48,623 | 43,765 | 34,521 | 26,481 | Upgrade | |
Revenue Growth (YoY) | 1.77% | 4.12% | 11.10% | 26.78% | 30.36% | 18.45% | Upgrade |
Cost of Revenue | 39,443 | 40,272 | 38,217 | 34,931 | 25,437 | 18,385 | Upgrade |
Gross Profit | 10,466 | 10,352 | 10,406 | 8,834 | 9,084 | 8,096 | Upgrade |
Selling, General & Admin | 8,697 | 8,881 | 8,310 | 8,158 | 7,351 | 4,988 | Upgrade |
Research & Development | - | - | - | - | - | 258 | Upgrade |
Operating Expenses | 9,795 | 9,979 | 9,369 | 9,364 | 8,399 | 5,675 | Upgrade |
Operating Income | 671 | 373 | 1,037 | -530 | 685 | 2,421 | Upgrade |
Interest Expense | -183 | -161 | -106 | -76 | -85 | -50 | Upgrade |
Interest & Investment Income | 63 | 22 | 31 | 67 | 40 | 24 | Upgrade |
Earnings From Equity Investments | - | - | - | - | -3 | 29 | Upgrade |
Currency Exchange Gain (Loss) | -406 | -77 | 532 | 1 | 149 | 84 | Upgrade |
Other Non Operating Income (Expenses) | 207 | 193 | 214 | 132 | 105 | 24 | Upgrade |
EBT Excluding Unusual Items | 352 | 350 | 1,708 | -406 | 891 | 2,532 | Upgrade |
Gain (Loss) on Sale of Investments | 56 | 56 | -3 | 154 | 20 | - | Upgrade |
Gain (Loss) on Sale of Assets | 23 | 23 | 1 | 7 | 6 | 59 | Upgrade |
Asset Writedown | -627 | -628 | -82 | -497 | -9 | -6 | Upgrade |
Other Unusual Items | - | - | -223 | -29 | -3 | 89 | Upgrade |
Pretax Income | -196 | -199 | 1,401 | -771 | 905 | 2,674 | Upgrade |
Income Tax Expense | 343 | 421 | 380 | 776 | 562 | 527 | Upgrade |
Earnings From Continuing Operations | -539 | -620 | 1,021 | -1,547 | 343 | 2,147 | Upgrade |
Minority Interest in Earnings | 4 | 4 | -20 | -6 | - | - | Upgrade |
Net Income | -535 | -616 | 1,001 | -1,553 | 343 | 2,147 | Upgrade |
Net Income to Common | -535 | -616 | 1,001 | -1,553 | 343 | 2,147 | Upgrade |
Net Income Growth | - | - | - | - | -84.02% | 62.78% | Upgrade |
Shares Outstanding (Basic) | 13 | 13 | 13 | 13 | 13 | 13 | Upgrade |
Shares Outstanding (Diluted) | 13 | 13 | 13 | 13 | 13 | 13 | Upgrade |
EPS (Basic) | -39.70 | -45.71 | 74.27 | -115.23 | 25.45 | 159.31 | Upgrade |
EPS (Diluted) | -39.70 | -45.71 | 74.27 | -115.23 | 25.45 | 159.31 | Upgrade |
EPS Growth | - | - | - | - | -84.02% | 62.78% | Upgrade |
Free Cash Flow | - | 538 | 759 | -1,753 | 511 | 1,358 | Upgrade |
Free Cash Flow Per Share | - | 39.92 | 56.32 | -130.07 | 37.92 | 100.76 | Upgrade |
Dividend Per Share | 12.000 | 12.000 | 10.000 | - | 20.000 | 15.000 | Upgrade |
Dividend Growth | 20.00% | 20.00% | - | - | 33.33% | - | Upgrade |
Gross Margin | 20.97% | 20.45% | 21.40% | 20.18% | 26.31% | 30.57% | Upgrade |
Operating Margin | 1.34% | 0.74% | 2.13% | -1.21% | 1.98% | 9.14% | Upgrade |
Profit Margin | -1.07% | -1.22% | 2.06% | -3.55% | 0.99% | 8.11% | Upgrade |
Free Cash Flow Margin | - | 1.06% | 1.56% | -4.00% | 1.48% | 5.13% | Upgrade |
EBITDA | 2,126 | 1,825 | 2,476 | 1,097 | 2,067 | 3,194 | Upgrade |
EBITDA Margin | 4.26% | 3.60% | 5.09% | 2.51% | 5.99% | 12.06% | Upgrade |
D&A For EBITDA | 1,455 | 1,452 | 1,439 | 1,627 | 1,382 | 773 | Upgrade |
EBIT | 671 | 373 | 1,037 | -530 | 685 | 2,421 | Upgrade |
EBIT Margin | 1.34% | 0.74% | 2.13% | -1.21% | 1.98% | 9.14% | Upgrade |
Effective Tax Rate | - | - | 27.12% | - | 62.10% | 19.71% | Upgrade |
Updated Jan 24, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.